Gilead’s Kite Pharma, Gadeta in Cell Therapy PactBy
Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, and Gadeta, an Utrecht, Netherlands-based company developing cancer immunotherapies based on gamma delta T cell receptors (TCRs), have formed a pact to develop gamma delta TCR therapies in various cancers.
Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration, and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones. In addition, Kite will make an upfront purchase of equity in Gadeta from Gadeta’s shareholders and may acquire additional equity in Gadeta upon achievement of certain R&D milestones. Kite will have the exclusive option to acquire Gadeta.
Gadeta has developed a proprietary technology to engineer alpha beta T cells with gamma delta TCRs, called TEGs, for potentially treating various hematological cancers and solid tumors. Gamma delta TCRs do not require expression of cell surface proteins for target recognition, and their ability to recognize targets under stress or metabolic conditions offer an approach to develop potentially effective cell therapies in solid tumors, according to Gilead Sciences.
Source: Gilead Sciences